Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acumen Pharmaceuticals, Inc. filings document a clinical-stage biopharmaceutical issuer focused on Alzheimer’s disease programs targeting toxic soluble amyloid beta oligomers. Its Form 8-K reports include operating and financial results, business highlights, Regulation FD presentation updates, clinical and nonclinical program disclosures, and material agreements related to Enhanced Brain Delivery development.
Proxy materials describe annual meeting voting matters, board elections, auditor ratification, and equity incentive plan approvals. The filing record also discloses ABOS common stock registered on the Nasdaq Global Select Market, emerging growth company status, governance changes, capital-structure matters, and clinical and regulatory disclosure categories tied to drug development.
Acumen Pharmaceuticals director Derrell Porter reported a series of option exercises and matching share sales in Common Stock. On June 15–17, 2026, he exercised options for a total of 19,500 shares at $1.07 per share and sold 32,300 shares in open-market transactions at weighted average prices around $2.32 per share, with individual trades ranging from $2.305 to $2.345. Following these transactions, Porter directly holds 35,500 shares of Acumen Pharmaceuticals Common Stock. The options exercised had vested in full on the date of the 2026 annual stockholder meeting.
ABOS files a Rule 144 notice for the sale of 13,040 shares. The filing lists the method as a Stock Option Exercise dated 06/17/2026 with cash proceeds. It also reports prior dispositions of 12,800 shares on 06/16/2026 for $29,767.68 and 6,460 shares on 06/15/2026 for $15,148.70.
ABOS reported a Form 144 notice for insider sales. The filing lists 12,800 shares of restricted common stock to be sold and shows 6,460 shares sold on 06/15/2026 for $15,148.70. The broker listed is Morgan Stanley Smith Barney LLC and the filing references NASDAQ.
Acumen Pharmaceuticals has nominated two Enhanced Brain Delivery (EBD) development candidates, ACU301 and ACU401, for Alzheimer’s disease under its collaboration with JCR Pharmaceuticals and has exercised its option to license and develop them. The candidates combine Acumen’s amyloid-beta oligomer–selective antibodies with JCR’s J-Brain Cargo blood-brain barrier–penetrating technology.
Both candidates showed strongly enhanced brain penetration in non-human primates, with antibody levels 14–40x higher than native antibodies at 24 hours, low anemia risk and no observed adverse events across tested species. They also demonstrated favorable stability and plasma pharmacokinetics after subcutaneous dosing. Acumen is conducting Investigational New Drug–enabling activities to support a planned IND submission in mid-2027 while continuing its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in early Alzheimer’s disease.
Acumen Pharmaceuticals director Nathan B. Fountain reported an open-market sale of 6,400 shares of Common Stock. The shares were sold on June 9, 2026 at a weighted average price of about $2.23 per share. After this transaction, he directly holds 48,150 shares of Acumen common stock.
Acumen Pharmaceuticals reported an equity compensation grant linked to director Dr. Laura Stoppel, as reflected on this Form 4 by RA Capital entities and related reporting persons. Dr. Stoppel received a restricted stock unit award covering 35,500 shares of common stock and a stock option for 53,250 shares with a $2.29 exercise price.
The RSUs and option will each vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, assuming Dr. Stoppel continues in service through that date. Under her arrangement with RA Capital Management, L.P., she holds these awards for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II and a separately managed account, and must deliver any net stock or cash received to the adviser to offset advisory fees. The reporting persons disclaim beneficial ownership of these awards and the underlying common stock beyond any pecuniary interest.
Acumen Pharmaceuticals director Nathan B. Fountain received new equity awards as part of his compensation. He was granted 35,500 shares of common stock in the form of restricted stock units, bringing his direct common stock holdings to 54,550 shares after the award. He also received stock options for 53,250 shares with an exercise price of $2.29 per share. Both the RSUs and options vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, provided he continues serving the company through that date.
Acumen Pharmaceuticals director Kimberlee C. Drapkin received new equity awards. She was granted 35,500 restricted stock units, each representing a right to receive one share of common stock. These RSUs vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, subject to continued service.
She also received stock options covering 53,250 shares at an exercise price of $2.29 per share, expiring on June 3, 2036, with the same vesting schedule. Following these awards, she directly holds 48,300 shares of Acumen common stock. The transactions reflect compensation-related grants rather than open-market purchases or sales.